|Day Low/High||13.14 / 13.71|
|52 Wk Low/High||8.63 / 44.75|
The biotech company plans to commercialize its treatment for AL amyloidosis, a disease that causes protein to build up in the blood.
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders
Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate
Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.